This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The weight loss drugs market size has grown exponentially in recent years. It will grow from $1.94 billion in 2023 to $2.87 billion in 2024 at a compound annual growth rate (CAGR) of 47.8%. The growth observed in the historical period can be attributed to several factors, including the increasing rates of obesity, changes in lifestyle, heightened awareness and education about weight-related issues, early diagnosis of medical conditions, and a general rise in healthcare expenditure. These factors collectively contributed to a greater demand for weight loss drugs as individuals sought solutions to address and manage weight-related concerns during the historical period.
The weight loss drugs market size has grown exponentially in recent years. It will grow from $2.87 billion in 2024 to $4.23 billion in 2025 at a compound annual growth rate (CAGR) of 47.6%. The growth in the historic period can be attributed to increasing obesity rates, lifestyle changes, awareness and education, early diagnosis of medical conditions, rising healthcare expenditure.
The weight loss drugs market size is expected to see exponential growth in the next few years. It will grow to $17.08 billion in 2029 at a compound annual growth rate (CAGR) of 41.7%. The growth in the forecast period can be attributed to increasing geriatric population, social media influence, fitness and wellness trends, cultural perception of beauty, pharmaceutical industry investments. Major trends in the forecast period include technological advancements, focus on non-prescription solutions, personalized medicine, combination therapies, product innovation, post-market surveillance.
Major companies in the weight loss drug market are focusing on the development of innovative products to better serve patients. One such example is Zepbound (tirzepatide) injection, a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-such as peptide-1 (GLP-1) receptor agonist. In November 2023, Eli Lilly and Company, a US-based pharmaceutical company, received FDA approval for tirzepatide injection (Zepbound) for chronic weight management in adults with overweight or obesity and at least one weight-related condition. Zepbound stands out as the first and only FDA-approved obesity treatment that activates both GIP and GLP-1 receptors, showing potential for commercial success.
In December 2023, Roche Holding AG, a Switzerland-based healthcare company, successfully acquired Carmot Therapeutics Inc. for $2.7 billion. This strategic acquisition granted Roche access to two obesity drug candidates, including an injectable ready for phase 2 clinical trials and a daily pill version in phase 1 trials. The acquisition aimed to strengthen Roche's position in the competitive and growing obesity drug market. Carmot Therapeutics Inc., a US-based clinical-stage biotechnology company, specializes in the discovery and development of disease-modifying therapies for obesity and diabetes.
Major companies operating in the weight loss drugs market report are Pfizer Inc., Roche, Merck & Co., AbbVie Inc., Novartis AG, Bristol Myers Squibb, Sanofi S.A., AstraZeneca PLC, LG Chem, GlaxoSmithKline, Takeda Pharmaceutical Company, Eli Lilly and Company, Bayer AG, Amgen Inc., Boehringer Ingelheim group, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd., Hisun Pharmaceutical, Taj Pharmaceuticals Ltd., Zhongshan Pharmaceutical Co. Ltd., Dm Pharma, Lunan Pharmaceutical Group Corporation, Wolfson Berg Ltd., Swiss Research Labs Ltd.
North America was the largest region in the Weight Loss Drugs market in 2024. The regions covered in the weight loss drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the weight loss drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Weight loss drugs refer to pharmaceutical substances designed to reduce appetite and food cravings, ultimately leading to a decrease in calorie intake and subsequent weight loss. These drugs undergo approval from the U.S. Food and Drug Administration (FDA) and are prescribed by healthcare professionals to treat individuals suffering from obesity or those who are overweight and have accompanying weight-related medical conditions such as high blood pressure, type 2 diabetes, or high cholesterol.
Weight loss drugs come in various forms, with the main types being liquid, tablets, and capsules. Weight loss liquids refer to formulations designed to assist in weight management and the reduction of body weight. These liquids are available through different distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies. They may serve various purposes, such as aiding in weight reduction, acting as fat absorption inhibitors, or boosting metabolism.
The weight loss drugs market consists of sales of appetite suppressants, fat absorption inhibitors, and metabolism boosters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The weight loss drugs market size has grown exponentially in recent years. It will grow from $1.94 billion in 2023 to $2.87 billion in 2024 at a compound annual growth rate (CAGR) of 47.8%. The growth observed in the historical period can be attributed to several factors, including the increasing rates of obesity, changes in lifestyle, heightened awareness and education about weight-related issues, early diagnosis of medical conditions, and a general rise in healthcare expenditure. These factors collectively contributed to a greater demand for weight loss drugs as individuals sought solutions to address and manage weight-related concerns during the historical period.
The weight loss drugs market size has grown exponentially in recent years. It will grow from $2.87 billion in 2024 to $4.23 billion in 2025 at a compound annual growth rate (CAGR) of 47.6%. The growth in the historic period can be attributed to increasing obesity rates, lifestyle changes, awareness and education, early diagnosis of medical conditions, rising healthcare expenditure.
The weight loss drugs market size is expected to see exponential growth in the next few years. It will grow to $17.08 billion in 2029 at a compound annual growth rate (CAGR) of 41.7%. The growth in the forecast period can be attributed to increasing geriatric population, social media influence, fitness and wellness trends, cultural perception of beauty, pharmaceutical industry investments. Major trends in the forecast period include technological advancements, focus on non-prescription solutions, personalized medicine, combination therapies, product innovation, post-market surveillance.
Major companies in the weight loss drug market are focusing on the development of innovative products to better serve patients. One such example is Zepbound (tirzepatide) injection, a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-such as peptide-1 (GLP-1) receptor agonist. In November 2023, Eli Lilly and Company, a US-based pharmaceutical company, received FDA approval for tirzepatide injection (Zepbound) for chronic weight management in adults with overweight or obesity and at least one weight-related condition. Zepbound stands out as the first and only FDA-approved obesity treatment that activates both GIP and GLP-1 receptors, showing potential for commercial success.
In December 2023, Roche Holding AG, a Switzerland-based healthcare company, successfully acquired Carmot Therapeutics Inc. for $2.7 billion. This strategic acquisition granted Roche access to two obesity drug candidates, including an injectable ready for phase 2 clinical trials and a daily pill version in phase 1 trials. The acquisition aimed to strengthen Roche's position in the competitive and growing obesity drug market. Carmot Therapeutics Inc., a US-based clinical-stage biotechnology company, specializes in the discovery and development of disease-modifying therapies for obesity and diabetes.
Major companies operating in the weight loss drugs market report are Pfizer Inc., Roche, Merck & Co., AbbVie Inc., Novartis AG, Bristol Myers Squibb, Sanofi S.A., AstraZeneca PLC, LG Chem, GlaxoSmithKline, Takeda Pharmaceutical Company, Eli Lilly and Company, Bayer AG, Amgen Inc., Boehringer Ingelheim group, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd., Hisun Pharmaceutical, Taj Pharmaceuticals Ltd., Zhongshan Pharmaceutical Co. Ltd., Dm Pharma, Lunan Pharmaceutical Group Corporation, Wolfson Berg Ltd., Swiss Research Labs Ltd.
North America was the largest region in the Weight Loss Drugs market in 2024. The regions covered in the weight loss drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the weight loss drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Weight loss drugs refer to pharmaceutical substances designed to reduce appetite and food cravings, ultimately leading to a decrease in calorie intake and subsequent weight loss. These drugs undergo approval from the U.S. Food and Drug Administration (FDA) and are prescribed by healthcare professionals to treat individuals suffering from obesity or those who are overweight and have accompanying weight-related medical conditions such as high blood pressure, type 2 diabetes, or high cholesterol.
Weight loss drugs come in various forms, with the main types being liquid, tablets, and capsules. Weight loss liquids refer to formulations designed to assist in weight management and the reduction of body weight. These liquids are available through different distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies. They may serve various purposes, such as aiding in weight reduction, acting as fat absorption inhibitors, or boosting metabolism.
The weight loss drugs market consists of sales of appetite suppressants, fat absorption inhibitors, and metabolism boosters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Weight Loss Drugs Market Characteristics3. Weight Loss Drugs Market Trends and Strategies4. Weight Loss Drugs Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Covid and Recovery on the Market32. Global Weight Loss Drugs Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Weight Loss Drugs Market34. Recent Developments in the Weight Loss Drugs Market
5. Global Weight Loss Drugs Growth Analysis and Strategic Analysis Framework
6. Weight Loss Drugs Market Segmentation
7. Weight Loss Drugs Market Regional and Country Analysis
8. Asia-Pacific Weight Loss Drugs Market
9. China Weight Loss Drugs Market
10. India Weight Loss Drugs Market
11. Japan Weight Loss Drugs Market
12. Australia Weight Loss Drugs Market
13. Indonesia Weight Loss Drugs Market
14. South Korea Weight Loss Drugs Market
15. Western Europe Weight Loss Drugs Market
16. UK Weight Loss Drugs Market
17. Germany Weight Loss Drugs Market
18. France Weight Loss Drugs Market
19. Italy Weight Loss Drugs Market
20. Spain Weight Loss Drugs Market
21. Eastern Europe Weight Loss Drugs Market
22. Russia Weight Loss Drugs Market
23. North America Weight Loss Drugs Market
24. USA Weight Loss Drugs Market
25. Canada Weight Loss Drugs Market
26. South America Weight Loss Drugs Market
27. Brazil Weight Loss Drugs Market
28. Middle East Weight Loss Drugs Market
29. Africa Weight Loss Drugs Market
30. Weight Loss Drugs Market Competitive Landscape and Company Profiles
31. Weight Loss Drugs Market Other Major and Innovative Companies
35. Weight Loss Drugs Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Weight Loss Drugs Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on weight loss drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for weight loss drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The weight loss drugs market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Liquid; Tablets; Capsules2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
3) By Application: Weight-Reducing Aid; Fat Absorption Inhibitors; Metabolic Boosters
Subsegments:
1) By Liquid: Syrups; Solutions; Suspensions2) By Tablets: Immediate-Release Tablets; Extended-Release Tablets
3) By Capsules: Hard Capsules; Softgel Capsules
Key Companies Mentioned: Pfizer Inc.; Roche; Merck & Co.; AbbVie Inc.; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Weight Loss Drugs market report include:- Pfizer Inc.
- Roche
- Merck & Co.
- AbbVie Inc.
- Novartis AG
- Bristol Myers Squibb
- Sanofi S.A.
- AstraZeneca plc
- LG Chem
- GlaxoSmithKline
- Takeda Pharmaceutical Company
- Eli Lilly and Company
- Bayer AG
- Amgen Inc.
- Boehringer Ingelheim group
- Novo Nordisk A/S
- Merck KGaA
- Teva Pharmaceutical Industries Ltd.
- Hisun Pharmaceutical
- Taj Pharmaceuticals Ltd
- Zhongshan Pharmaceutical Co. Ltd.
- Dm Pharma
- Lunan Pharmaceutical Group Corporation
- Wolfson Berg Ltd.
- Swiss Research Labs Ltd.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | March 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 4.23 Billion |
Forecasted Market Value ( USD | $ 17.08 Billion |
Compound Annual Growth Rate | 41.7% |
Regions Covered | Global |
No. of Companies Mentioned | 26 |